UK purchasing policies quash innovation, hurt industry
This article was originally published in Clinica
UK purchasers are short-sighted when it comes to assessing which devices to buy and are still focusing too narrowly on equating value for money with price alone, which is catastrophic for UK industry and spells death to innovation - so says Malcolm Carlisle, group managing director of Eschmann holdings.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.